Clinicopathological data of 256 patients in the anlotinib group
| Characteristics | n = 256 (%) |
| Age (years) | |
| ≤ 60 years | 137 (53.52) |
| > 60 years | 119 (46.48) |
| Gender | |
| Male | 157 (61.33) |
| Female | 99 (38.67) |
| Pathology | |
| Adenocarcinoma | 201 (78.52) |
| Squamous cell carcinoma or adenosquamous
carcinoma | 44 (17.19) |
| Other subtypes | 11 (4.3) |
| Driver gene EGFR | |
| Wild type (-) | 172 (67.19) |
| Mutant type (+) | 84 (32.81) |
| Driver gene ALK | |
| Wild type (-) | 248 (98.02) |
| Mutant type (+) | 5 (1.98) |
| Unclear | 3 |
| Clinical staging | |
| Stage III B | 12 (4.69) |
| Stage IV | 244 (95.31) |
| Metastasis | |
| Number of metastases ≤ 3 | 155 (60.55) |
| Number of metastases > 3 | 101 (39.45) |
| History of tumor surgery | |
| Yes | 136 (53.13) |
| No | 120 (46.88) |
| Number of previous chemotherapy regimens | |
| 2 | 146 (57.03) |
| > 2 | 110 (42.97) |
| Previous chemotherapeutic regimen | |
| Pemetrexed + Platinum | 182 (71.09) |
| Docetaxel + Platinum | 165 (64.45) |
| Paclitaxel + Platinum | 81 (31.64) |
| Vinorelbine + Platinum | 67 (26.17) |
| Gemcitabine + Platinum | 138 (53.91%) |
| History of radiotherapy | |
| No | 154 (60.16) |
| Yes | 102 (39.84) |
| History of targeted medication | |
| No | 115 (44.92) |
| Yes | 141 (55.08) |
| ECOG | |
| 0 | 54 (21.09) |
| 1 | 202 (78.91) |